Instrument Inactif

Communiqués OKYO Pharma Limited London S.E.

Actions

OKYO

GG00BMFG5F62

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

OKYO Pharma Announces Participation in May 2024 Investor Conferences	08/05	AQ
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)	30/04	AQ
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024	09/04	AQ
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery	02/04	AQ
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	22/03	AQ
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event	20/03	AQ
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	09/02	AQ
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board	31/01	AQ
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease	08/01	AQ
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024	05/01	AQ
OKYO PHARSADR : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K	18/12	PU
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	04/12	AQ
Notice of AGM: December 2023	28/11	PU
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction	31/10/23	AQ
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)	09/10/23	AQ
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")	05/10/23	AQ
OKYO Pharma's Advancing Clinical Mission to Better Treat Eye Disease Sends Shares 89% Higher Since August ($OKYO)	05/10/23	AQ
OKYO PHARSADR : Securities Purchase Agreement - Form 6-K	15/09/23	PU
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares	15/09/23	AQ
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares	14/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués OKYO Pharma Limited London S.E.

Actions

OKYO

GG00BMFG5F62

Communiqués

Filtres